Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies
Privigen Randomized Study for Pediatric CIDP
Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP
See complete study information on clinicaltrials.gov.
IRB Study ID:
23875646
Study Sponsor:
CSL Behring
Full IRB Study Title:
Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP
We are currently recruiting
If you are interested in this study or have questions about your child's eligibility, please contact:
Hilary Tonni, Rebecca D. Considine Research Institute: 330-543-4734
Who May Qualify:
Male or female patients 2 to <17 years of age with confirmed or possible chronic inflammatory demyelinating polyneuropathy (CIDP)
Who Does NOT Qualify:
Patients with:
- History or family history of inherited neuropathy
- Diagnosed developmental delay or regression
- History of thrombotic episode
- Known or suspected hypersensitivity to Privigen
- Known allergic or other severe reactions to blood products
- Female subject of childbearing potential either not using or not willing to use a medically reliable method of contraception or not sexually abstinent during the study
- Pregnant or breastfeeding mother
Lead Investigator
Ian Rossman, MD, PhD
Pediatric Neurologist
NeuroDevelopmental Science CenterPediatric Neuromuscular ClinicPediatric NeurologyMitochondrial Center
